Latest Medtech News
Updated 31 August 2026
Boston Scientific is one of the most acquisitive companies in MedTech, closing multiple tuck-in and billion-dollar deals almost every year across cardiology, electrophysiology, urology, and pain management. This page tracks the moves worth knowing about.
We update this tracker regularly with Boston Scientific's most relevant recent activity, plus a look back at the deals that shaped the company since 2019.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like these. Subscribe to our Industry Insights for weekly coverage.
Boston Scientific in 2026: What's Happened So Far
Boston Scientific Completes Acquisition of Penumbra (January 2026) Added neurovascular and peripheral thrombectomy devices to Boston Scientific's portfolio.
Boston Scientific Completes Acquisition of Valencia Technologies (April 2026) Added the eCoin implantable tibial nerve stimulation system for urge urinary incontinence to Boston Scientific's urology business.
Boston Scientific Closes Acquisition of Nalu Medical (2026) Added a peripheral nerve stimulation platform to Boston Scientific's pain management franchise.
Boston Scientific Invests $1.5B in TAVR Developer MiRus (2026) A strategic investment in transcatheter aortic valve replacement technology.
Boston Scientific Deal History
Boston Scientific Completes Acquisition of Bolt Medical ($664M, April 2025) Added a laser-based intravascular lithotripsy platform for coronary and peripheral artery disease, following a string of late-2024 acquisitions in the same space.
Boston Scientific Announces Agreement to Acquire SoniVie (March 2025) A renal denervation technology developer, expanding Boston Scientific's hypertension treatment portfolio.
Boston Scientific Completes Acquisition of Axonics ($3.7B, November 2024) Boston Scientific's largest deal of the year, entering the sacral neuromodulation space for urinary and bowel dysfunction.
Boston Scientific Completes Acquisition of Silk Road Medical ($1.26B, September 2024) Added TCAR technology and a differentiated position in carotid artery disease treatment.
Boston Scientific Wins FDA Approval for Farapulse Pulsed Field Ablation System (January 2024) A major electrophysiology milestone for the atrial fibrillation treatment Boston Scientific first invested in back in 2014.
Boston Scientific Acquires Apollo Endosurgery ($615M, 2023) Expanded Boston Scientific's endoluminal surgery portfolio and marked its entry into the endobariatric market.
Boston Scientific Acquires Majority Stake in Acotec Scientific Holdings (2023) Strengthened Boston Scientific's presence in China's vascular disease treatment market.
Boston Scientific Completes Acquisition of Baylis Medical ($1.75B, February 2022) Added transseptal access technology used in AFib ablation, left atrial appendage closure, and mitral valve procedures, Boston Scientific's largest deal of 2021 to 2022.
Boston Scientific Seizes an Opportunity in Mitral Valve Repair (December 2018)
Boston Scientific Launches Spectra WaveWriter SCS in Europe (January 2019)
Boston Scientific Earns CE Mark for Watchman FLX (March 2019) The next-generation left atrial appendage closure device, designed to reduce stroke risk in atrial fibrillation patients.
Boston Scientific Gets Into Spine with $465M Vertiflex Buy (June 2019) Added the Superion lumbar spinal stenosis device to Boston Scientific's pain management portfolio.
Boston Scientific Completes Acquisition of BTG ($4.2B, August 2019) Boston Scientific's second-largest acquisition ever at the time, expanding into interventional oncology and vascular disease devices.
Boston Scientific Launches Tool to Monitor Radiofrequency Energy (June 2020)
Boston Scientific Completes Acquisition of Farapulse (Q3 2021) Boston Scientific's first move into pulsed field ablation, a technology it had invested in since 2014, and the foundation for its 2024 FDA approval.
Boston Scientific Completes Acquisition of Preventice Solutions ($925M, 2021) Added cardiac diagnostics and remote monitoring capabilities.
First Patients Enrolled in Trial for Boston Scientific's SpaceOAR Vue Hydrogel (Feburary 2022)
This page is updated on a monthly basis to reflect Boston Scientific's ongoing activity.
